Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16241
Title: Fully automated synthesis of [(18) F]fluoro-dihydrotestosterone ([(18) F]FDHT) using the FlexLab module
Austin Authors: Ackermann, Uwe ;Lewis, Jason S;Young, Kenneth ;Morris, Michael J;Weickhardt, Andrew;Davis, Ian D;Scott, Andrew M 
Affiliation: Austin Health, Heidelberg, Victoria, Australia
Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia
Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Victoria, Australia
School of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia
School of Cancer Medicine, LaTrobe University, Bundoora, Victoria, Australia
Radiochemistry & Molecular Imaging Probe Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Monash University Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia
Eastern Health, Melbourne, Victoria, Australia
Issue Date: Aug-2016
metadata.dc.date: 2016-07-04
Publication information: Journal of Labelled Compounds and Radiopharmaceuticals 2016; 59(10): 424-428
Abstract: Imaging of androgen receptor expression in prostate cancer using F-18 FDHT is becoming increasingly popular. With the radiolabelling precursor now commercially available, developing a fully automated synthesis of [(18) F] FDHT is important. We have fully automated the synthesis of F-18 FDHT using the iPhase FlexLab module using only commercially available components. Total synthesis time was 90 min, radiochemical yields were 25-33% (n = 11). Radiochemical purity of the final formulation was > 99% and specific activity was > 18.5 GBq/µmol for all batches. This method can be up-scaled as desired, thus making it possible to study multiple patients in a day. Furthermore, our procedure uses 4 mg of precursor only and is therefore cost-effective. The synthesis has now been validated at Austin Health and is currently used for [(18) F]FDHT studies in patients. We believe that this method can easily adapted by other modules to further widen the availability of [(18) F]FDHT.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16241
DOI: 10.1002/jlcr.3417
ORCID: 0000-0002-9066-8244
0000-0002-6656-295X
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/27378195
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

4
checked on Dec 2, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.